SEC Form 10-Q filed by TScan Therapeutics Inc.
$TCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $12.00 | Buy | BTIG Research |
| 5/13/2024 | $11.00 | Buy | Needham |
| 6/22/2023 | $8.00 | Outperform | Wedbush |
| 12/16/2021 | $21.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | Outperform | Cowen & Co. | |
| 8/10/2021 | $22.00 | Overweight | Barclays |
| 8/10/2021 | $22.00 | Overweight | Morgan Stanley |
| 8/10/2021 | $21.00 | Buy | Jefferies |